Reimbursement of Sativex® (Delta 9 Tetrahydrocannabinol (THC)/Cannabidiol (CBD)) Oromucosal Spray
![Department of Health - Authorisation of Opioid Substitution Treatment Department of Health - Authorisation of Opioid Substitution Treatment](https://ipu.ie/wp-content/uploads/2023/07/pharma-looking-medicines-1024x680.png)
The HSE has approved Sativex® oromucosal spray under High Tech Arrangements effective 1 October 2023 through a Managed Access Protocol (HSE-MAP) that will enable individual reimbursement approval for patients who meet the criteria outlined in the HSE-MAP. For more information, see HSE Circular 027/23.